Exelixis (EXEL) moves to 'Buy' with a de-risked pipeline, strong financials, and breakthrough phase 3 results. See more analysis here.

Updates in AxSpA from EULAR 2025 include 3-year data for bimekizumab, definition of difficult-to-manage subgroups, ...

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug for a type of hereditary swelling disorder, sending its shares up 33.3% in premarket trading.

Exelixis EXEL has put up a stellar performance so far this year. Shares of the biotech company have rallied 35.2% in the past ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel ...

An Ozempic-like drug prescribed for diabetes has been found to reduce the frequency of debilitating migraine. Researchers say ...

Dr Hilda Kyarisiima, Senior Medical Officer in the Vector Control Division at the Ministry of Health, said the pilot was carried out between March and May 2025 in Buseruka and Kiganja sub-counties.